astrocytoma, IDH-mutant, grade 2
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0081256
Name astrocytoma, IDH-mutant, grade 2
Definition An IDH-mutant anaplastic astrocytoma that is characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system.
Source DiseaseOntology.org
Alt Ids
Xrefs
ICDO:9400/3
Path disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma anaplastic astrocytoma IDH-mutant anaplastic astrocytoma astrocytoma, IDH-mutant, grade 2

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
IDH1 act mut Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH2 act mut Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH1 R132X Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH2 R172X Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH1 R132C Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH1 R132G Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH1 R132H Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH1 R132L Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH1 R132S Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH2 R172M Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH2 R172K Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH2 R172W Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH2 R172S Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
IDH2 R172G Vorasidenib astrocytoma, IDH-mutant, grade 2 sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06478212 Phase Ib/II Temozolomide + Vorasidenib Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma Active, not recruiting USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | AUT 2
NCT06809322 Phase III Vorasidenib Vorasidenib Maintenance for IDH Mutant Astrocytoma (VIGOR) Recruiting NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT 0
NCT06894979 Phase I AZD1390 Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma Recruiting USA 0